Press releases

22
Dec 2023
21:30 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Read more
17
Nov 2023
21:30 E.S.T.

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Read more
15
Nov 2023
07:30 E.S.T.

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Read more
6
Nov 2023
21:30 E.S.T.

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Read more
2
Nov 2023
20:30 E.S.T.

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Read more
1
Nov 2023
20:30 E.S.T.

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

Read more
1
Nov 2023
07:00 E.S.T.

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Read more
31
Oct 2023
20:30 E.S.T.

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more
24
Oct 2023
20:30 E.S.T.

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Read more
12
Oct 2023
08:30 E.S.T.

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US